Patent · US Active

Formulations and methods for direct sodium removal in patients having heart failure and/or severe renal dysfunction

US11844890B2 · kind B2 · utility

0Cited by

218References

30Claims

0Family size

Assignee

Sequana Medical NV · CH

Inventors

Jeffrey Testani · New Haven, US
Christopher McIntyre · Middletown, US
Ian CROSBIE · London, GB
Oliver Goedje · Deining, DE

Key dates

Filing date	Jan 20, 2023
Grant date	Dec 19, 2023
Priority date	—
Expiry date	Jan 20, 2043

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61M2210/1085
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.